Concepedia

Carlos Rojas

CR

4

Publications

62

Citations

4

H-Index

2023

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Vall d'Hebron Hospital Universitari

Jena University Hospital

Merck & Co., Inc., Rahway, NJ, USA (United States)

Vall d'Hebron Institute of Oncology

Carlos Rojas is an author at Memorial Sloan Kettering Cancer Center specializing in cancer therapeutics, oncology, and medicine.

Top concepts

MedicineOncologyCancer TherapyPharmacotherapyRadiation OncologySurgeryUrologyPathologyNephrologyPharmacology

Publications per year

2023–2024

4

Publications

4

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

Robert J. Motzer, Axel Bex, Paul Russo et al. · Journal of Clinical Oncology · 2024 · 20 citations · Full text

First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results.

Patricio Yañez, Irit Ben‐Aharon, Carlos Rojas et al. · Journal of Clinical Oncology · 2023 · 15 citations

First-line Lenvatinib, Chemotherapy Versus Chemotherapy, Oncology +14

663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

Carlos Rojas, Rosalyn A. Juergens, Adrian G. Sacher et al. · Annals of Oncology · 2023 · 14 citations

Oncology, Solid Tumors, Medicine +8

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

Robert J. Motzer, Axel Bex, Paul Russo et al. · Journal of Clinical Oncology · 2024 · 13 citations

Surgical Oncology, Multimodality, Surgery +16

Rows per page

1–4 of 4